SeraCare Life Sciences Launches First-Ever Tumor Mutational Burden Reference Materials

SeraCare Life Sciences Launches First-Ever Tumor Mutational Burden Reference Materials 3MILFORD, Mass., Oct. 31, 2019 /PRNewswire/ — SeraCare Life Sciences, a part of the LGC Clinical Diagnostics Business Unit and a manufacturing company and leading partner to global in vitro diagnostics manufacturers and clinical labs, announced today the commercial launch of the first genomic DNA (gDNA) and formalin-fixed paraffin-embedded…
News story published on 2019-11-01T09:29:00.0000000Z